Sterling Biomedical is working on an antimicrobial platform technology which prevents bacterial colonization and surface biofilms on implantable devices without generating bacterial resistance. The Company relies on its expertise in biomaterials science and controlled delivery to develop antimicrobial implants. Sterling seeks to outlicense its technology to a suitable strategic partner. Sterling has developed an antimicrobial platform technology applicable to many medical devices. Sterling relies on its expertise in biomaterials science, control delivery and device manufacturing. Our first target is the lucrative venous catheter market. Because catheters using our technology will not only reduce complications, but can be produced at competitive prices, these products conform to a managed care market that stresses reduced clinical outcomes costs. Solution: Our silver ion antimicrobial technology is effective for several months, and is subject to a 510(k) âsubstantial equivalencyâ approval process. Because the silver salts are incorporated into the polyurethane prior to extrusion, all catheter surfaces are actively resistant to bacterial colonization and subsequent biofilm formati
